NCT04998552 is a NA clinical trial of Cyberknife in Pancreas Adenocarcinoma, sponsored by Capital Health System, Inc.

Who is sponsoring NCT04998552?

NCT04998552 is sponsored by Capital Health System, Inc.

What drugs are being tested in NCT04998552?

Interventions in NCT04998552: Cyberknife.

What condition does NCT04998552 study?

NCT04998552 studies Pancreas Adenocarcinoma.

Is NCT04998552 still recruiting?

NCT04998552 is currently recruiting now. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT04998552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Recruiting now NA Last updated 31 March 2023

What this trial tests

NA trial testing Cyberknife in Pancreas Adenocarcinoma in 10 participants. Currently enrolling.

Timeline

22 June 2021

Primary endpoint
22 June 2027

22 June 2027

Quick facts

Lead sponsor	Capital Health System, Inc
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	10
Start date	22 June 2021
Primary completion	22 June 2027
Estimated completion	22 June 2027
Sites	1 location across United States

Drugs / interventions tested

Cyberknife — full drug profile →

Conditions studied

Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →

Sponsor

Capital Health System, Inc

Who can join

18 and older, any sex, with Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreas Adenocarcinoma

Currently open trials in the same condition.

NCT07043270 — 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · Phase 2 · recruiting
NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
NCT06497777 — The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04998552 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Health System, Inc
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04998552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing